12,640 Shares in Quest Diagnostics Incorporated $DGX Purchased by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd bought a new stake in Quest Diagnostics Incorporated (NYSE:DGX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 12,640 shares of the medical research company’s stock, valued at approximately $2,270,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in DGX. Pinnacle Bancorp Inc. grew its position in Quest Diagnostics by 126.9% in the second quarter. Pinnacle Bancorp Inc. now owns 152 shares of the medical research company’s stock worth $27,000 after acquiring an additional 85 shares during the period. MTM Investment Management LLC acquired a new position in shares of Quest Diagnostics in the 2nd quarter valued at $29,000. AlphaQuest LLC grew its holdings in shares of Quest Diagnostics by 18,400.0% during the 2nd quarter. AlphaQuest LLC now owns 185 shares of the medical research company’s stock worth $33,000 after purchasing an additional 184 shares during the period. Ameritas Advisory Services LLC purchased a new position in shares of Quest Diagnostics during the 2nd quarter worth $35,000. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Quest Diagnostics by 1,495.2% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 335 shares of the medical research company’s stock worth $57,000 after purchasing an additional 314 shares during the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Activity

In other Quest Diagnostics news, Director Gary M. Pfeiffer sold 1,482 shares of the firm’s stock in a transaction that occurred on Wednesday, October 22nd. The shares were sold at an average price of $182.40, for a total transaction of $270,316.80. Following the sale, the director owned 29,431 shares of the company’s stock, valued at approximately $5,368,214.40. This trade represents a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael E. Prevoznik sold 227 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $188.13, for a total transaction of $42,705.51. Following the sale, the senior vice president owned 38,117 shares of the company’s stock, valued at $7,170,951.21. This represents a 0.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,172 shares of company stock worth $5,639,001 in the last three months. Corporate insiders own 8.16% of the company’s stock.

Quest Diagnostics Stock Performance

Shares of Quest Diagnostics stock opened at $186.10 on Thursday. The business has a 50-day simple moving average of $183.21 and a 200-day simple moving average of $178.40. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.04 and a current ratio of 1.13. Quest Diagnostics Incorporated has a one year low of $148.70 and a one year high of $197.55. The company has a market cap of $20.70 billion, a PE ratio of 21.84, a P/E/G ratio of 2.31 and a beta of 0.58.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.09. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The company had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same quarter in the previous year, the firm earned $2.30 earnings per share. The firm’s quarterly revenue was up 13.2% on a year-over-year basis. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. On average, equities research analysts forecast that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 28th. Stockholders of record on Tuesday, January 13th will be given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 13th. Quest Diagnostics’s dividend payout ratio is currently 37.56%.

Analyst Ratings Changes

Several research analysts have weighed in on DGX shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Quest Diagnostics in a research note on Wednesday, October 8th. Baird R W downgraded shares of Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 25th. Morgan Stanley set a $207.00 target price on Quest Diagnostics and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. William Blair restated an “outperform” rating on shares of Quest Diagnostics in a research report on Wednesday, July 23rd. Finally, Wall Street Zen cut Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $196.31.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.